Evidence map›Paper›PMID 41041325›Full record

ArticleFrontiers in immunology2025

B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.

Yili Xu, Liang Wang, Chunming Jiang, Dong Sun, Min Yang, Jin Liu, Xiaobin Liu, Cheng Wan, Caixia Liu, Bo Zhang and 19 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Yili XuDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Liang WangDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Chunming JiangDepartment of Nephrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Dong SunDepartment of Nephrology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Min YangDepartment of Nephrology, The First People's Hospital of Chang Zhou City, Changzhou, China.
Jin LiuClinical Medicine Research Institution, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Xiaobin LiuDepartment of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Cheng WanDepartment of Nephrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Caixia LiuDepartment of Nephrology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Bo ZhangDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Guangyu BiDepartment of Nephrology, Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China.
Lianhua ChenDepartment of Nephrology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Liyuan ZhangDepartment of Nephrology, The first people's hospital of Lianyungang, Lianyungang, China.
Guoyuan LuDepartment of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Liang ZhangDepartment of Nephrology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.
Hua ZhouDepartment of Nephrology, The First People's Hospital of Chang Zhou City, Changzhou, China.
Xiaobo ZhangDepartment of Nephrology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Gang ZhouDepartment of Nephrology, Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China.
Fang LuDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Chengning ZhangDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Bin SunDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Ming ZengDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Shuaibo BianDepartment of Nephrology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.
Li ZhangDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Ningning WangDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Lei ShenDepartment of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yanggang YuanDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Changying XingDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Huijuan MaoDepartment of Nephrology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study assessed the safety and efficacy of B cell- and anti-PLA2R antibody-targeted low-dose rituximab therapy in patients with idiopathic membranous nephropathy (IMN). Methods: This was a multicenter, investigator-initiated, open-label, prospective cohort study. Patients were recruited from 10 hospitals in the east coastal region of China between November 1 Results: A total of 140 patients were included in the sta tistical analysis, which was completed on June 10 Discussion: B cell- and anti-PLA2R antibody-targeted rituximab therapy may be a cost-effective and safe alternative for patients with IMN. Randomized controlled trials with larger samples are needed to confirm these findings. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=42793, identifier ChiCTR1900026382.

Indexed as

B-LymphocytesGlomerulonephritis, MembranousReceptors, Phospholipase A2RituximabAdultAgedAutoantibodiesChinaFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAutoantibodiesPLA2R1 protein, humanReceptors, Phospholipase A2Rituximabidiopathic membranous nephropathynon-randomized clinical trialsprospective cohortrituximabtargets driven

Identifiers

PMID41041325
PMCPMC12484018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.